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Abstract
Vitamin D deficiency has been linked with an increased risk of incident all-cause dementia
and Alzheimer’s disease. The aim of the current study was to explore the potential mecha-
nisms underlying these associations by determining whether low vitamin D concentrations
are associated with the development of incident cerebrovascular and neurodegenerative neu-
roimaging abnormalities. The population consisted of 1,658 participants aged65 years from
the US-based Cardiovascular Health Study who were free from prevalent cardiovascular dis-
ease, stroke and dementia at baseline in 1992–93. Serum 25-hydroxyvitamin D (25(OH)D)
concentrations were determined by liquid chromatography-tandemmass spectrometry from
blood samples collected at baseline. The first MRI scan was conducted between 1991–1994
and the secondMRI scan was conducted between 1997–1999. Change in white matter
grade, ventricular grade and presence of infarcts betweenMRI scan one and two were used
to define neuroimaging abnormalities. During a mean follow-up of 5.0 years, serum 25(OH)D
status was not significantly associated with the development of any neuroimaging abnormali-
ties. Using logistic regression models, the multivariate adjusted odds ratios (95% confidence
interval) for worsening white matter grade in participants who were severely 25(OH)D defi-
cient (<25 nmol/L) and deficient (25–50 nmol/L) were 0.76 (0.35–1.66) and 1.09 (0.76–1.55)
compared to participants with sufficient concentrations (50 nmol/L). The multivariate
adjusted odds ratios for ventricular grade in participants who were severely 25(OH)D deficient
and deficient were 0.49 (0.20–1.19) and 1.12 (0.79–1.59) compared to those sufficient. The
multivariate adjusted odds ratios for incident infarcts in participants who were severely 25
(OH)D deficient and deficient were 1.95 (0.84–4.54) and 0.73 (0.47–1.95) compared to those
sufficient. Overall, serum vitamin D concentrations could not be shown to be associated with
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Introduction
Recent prospective studies have found that low serum vitamin D concentrations are associated
with an increased risk of incident all-cause dementia [1], Alzheimer disease (AD) dementia
[1,2] and non-AD dementias [3]. Neuroimaging techniques could provide an insight into the
potential mechanisms underlying these associations. Cross-sectional studies have consistently
found that lower vitamin D concentrations are associated with an increased risk of neuroimag-
ing abnormalities [4–19]. These include cerebrovascular and neurodegenerative pathologies
implicated in the development of dementia, such as white matter hyperintensities
[4,10,12,13,15], enlarged ventricular volume [8], large vessel infarcts [4] and lacunar infarcts
[15]. However, the temporal association cannot be inferred from cross-sectional studies.
In the only prospective study reported, vitamin D concentrations were not associated with
white matter hyperintensity progression, incident white matter hyperintensity score or incident
infarcts in 888 healthy adults with a mean age of 62.3 years over a ten year follow-up period
[20]. However, approximately 40% of participants were lost to follow-up, which might have
biased the findings towards the null due to non-random attrition. To expand, low vitamin D
concentrations could have led to the development of cerebrovascular abnormalities, which in
turn resulted in participants dropping out before the follow-up scan.
We recently observed that low vitamin concentrations were associated with a substantially
increased risk of all-cause dementia and AD in 1,658 elderly adults from the US-based Cardio-
vascular Health Study (CHS) [1]. In order to investigate the potential mechanisms underlying
these associations we investigated whether vitamin D concentrations were associated with the
risk of developing cerebrovascular and neurodegenerative neuroimaging abnormalities in the
same population.
Materials and Methods
Participants
Participants were selected from the CHS, a large prospective population-based cohort in the
US designed to investigate the underlying causes of cardiovascular disease in older men and
women. Further details regarding the CHS have been published elsewhere [21]. The initial
cohort consisted of 5,888 participants, of these 4,692 ambulatory participants had complete
exam data in 1992–93. Serum 25-hydroxyvitamin D (25(OH)D) concentrations were not mea-
sured in 1,424 participants who had prevalent cardiovascular disease or stroke (one or more of
the following: coronary heart disease, congestive heart failure, claudication, atrial fibrillation,
pacemaker, implantable cardioverter-defibrillator, stroke or transient ischemic attack), deter-
mined by medical records, electrocardiograph findings and self-report [22]. Out of 3,268 par-
ticipants, a further 945 were excluded as they had insufficient serum volumes for the vitamin D
assay to be performed (<500 μl). Additional exclusions were made on the basis of missing
adjudicated dementia status (n = 596) and prevalent dementia at baseline (n = 69). Of the
1,658 participants, for both MRI scans 1 and 2, 1,017 (61.3%) had complete white matter grade
information, 994 (60.0%) had complete ventricular grade information and 1,108 had complete
infarct information (66.8%). Those lost to follow-up (defined as participants with missing data
for at least one of the three neuroimaging outcomes for the second MRI scan, N = 668) were
more likely to be older (mean [SD], 74.6 [5.0] years vs 73.0 [4.0] years, p<0.001), had lower
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serum 25(OH)D concentrations (mean [SD], 63.3 [25.9] nmol/L vs 66.1 [26.8] nmol/L,
p = 0.03), and were less educated (25.6% vs 19.8% did not finish high school, 54.2% vs 55.5%
finished high school/some college/vocational qualifications, and 20.2% vs 24.7% completed
college or professional qualifications, p = 0.007), but they were no more likely to be female
(71.0% vs 68.1%, p = 0.21) or non-white (11.7% vs 12.9%, p = 0.45). In the main analyses, mul-
tiple imputation was used to restore the missing data for all neuroimaging outcomes resulting
in a final sample size of 1,658. The following institutional review boards at each participating
institution approved the research protocols; the University of California, Johns Hopkins Uni-
versity, Wake Forest University School of Medicine and University of Pittsburgh. All partici-
pants provided written informed consent during the course of the study.
Serum 25(OH)D Measurement
Serum samples were collected once at baseline in 1992–93 and were stored at -70°C at the Lab-
oratory for Clinical Biochemistry Research at the University of Vermont, and measurements
were performed by the University of Washington Clinical Nutrition Research Unit in 2008
[23]. Total 25(OH)D (the sum of 25(OH)D2 and 25(OH)D3) was measured using liquid chro-
matography and tandem mass spectrometry (LC-MS) on a Waters Quattro micro mass spec-
trometer (Waters, Milford, Massachusetts); the inter-assay coefficient of variation was<3.4%
[22]. Calibration of serum 25(OH)D concentrations were verified using SRM 972 from the
National Institutes Standards and Technology [24]. Serum 25(OH)D was categorised using the
following clinically relevant cut points:<25 nmol/L (severely deficient),25 nmol/L to<50
nmol/L (deficient), 50 nmol/L (sufficient) [1].
Neuroimaging Outcomes
Out of the original 5,888 participants, a total of 2,116 underwent both MRI scans, with the first
scan conducted between 1991–1994 and the second scan conducted between 1997–1999. The
MRI scans were performed on either General Electric or Picker 1.5 Tesla scanners at three field
centres and on a 0.35 Tesla Toshiba instrument at one field center [25]. The scanning protocol
involved a sagittal T1 weighted localizing scan, with subsequent axial spin density/T2 and T1
axial weighted scans aligned parallel to the anterior commissure-posterior commissure line
[26]. Neuroradiologists who were unaware of clinical and demographic information estimated
white matter and ventricular grades on a ten-point scale from 0–9 [25]. A higher grade indi-
cates either more white matter disease, as defined by total extent of periventricular and subcor-
tical white matter abnormalities, or enlarged ventricular volume [27]. In 2001–2002 white
matter and ventricular grade were re-estimated with the baseline and follow-up scans read in a
side-by-side fashion in order to improve rating reliability [28]. Infarcts were defined as either
absent or present. The presence of infarcts was based on evidence of an area of abnormal signal
intensity in a vascular distribution that lacked mass effect on the MRI scans [29]. All infarcts
were3mm in size as abnormalities<3mm could not be reliably detected. Change variables
were derived for white matter and ventricular grade by subtracting the baseline scan grade
from the follow-up scan grade. Due to the low number of participants who worsened by more
than one grade for white matter (n = 45) and ventricular grade (n = 3), each variable was fur-
ther categorised into two groups. The first group was defined as no change and the second
group was defined as worsening grade by1 between baseline and follow-up scans. 2 partici-
pants who had an improved white matter grade of one at follow-up and 6 participants who had
an improved ventricular grade of one at follow-up were classified as no change. Similarly, a
binary variable was derived for infarcts with the first group defined as no incident infarcts and
the second group defined as developing incident infarcts.
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Covariates
We identified the following variables as potential confounders in the relationship between 25
(OH)D concentrations and the development of neuroimaging abnormalities: age in years, season
of blood collection (categories used for analysis—December-February; March-May; June-August;
September-November), education status (did not finish high school; finished high school/some
college/vocational qualifications; college/professional qualifications), sex, body mass index (BMI
in kg/m2), smoking (non-smoker; current smoker), alcohol consumption (National Institute on
Alcohol Abuse and Alcoholism definitions:- non-drinkers; moderate drinkers (women—7
drinks/week; men—14 drinks/week); heavy drinkers (women—>7 drinks/week; men—>14
drinks/week)), significant depressive symptoms (score8 on the revised 10 item Center for Epi-
demiologic Studies Depression Scale [30]) and length of follow-up in years.
Multiple Imputation
Multiple imputation by chained equations was used to account for the missing data observed
in the neuroimaging outcomes as well as the covariates [31]. One participant was excluded
from the imputed white matter model as they had a score of nine for the first scan, whilst 415
participants with prevalent infarcts were excluded from the imputed infarcts model. This
resulted in a total of 1,658 participants for ventricular grade, 1,657 for white matter grade and
1,243 for infarcts. 100 imputations were generated for each variable with missing data. The fol-
lowing predictive variables were entered into the imputation model: age, sex, education,
depressive symptoms, alcohol consumption, smoking, BMI, season of blood collection, ethnic-
ity, hypertension, diabetes, kidney function, continuous change in 3MSE score per year from
baseline to participants last follow-up, incident dementia, incident stroke, length of follow-up,
baseline white matter grade, baseline ventricular grade and baseline infarcts. The imputation
models were run separately for each neuroimaging outcome.
Statistical Analysis
Multivariate logistic regression models were used to investigate the association between base-
line serum 25(OH)D and the risk of developing incident neuroimaging abnormalities. Multiple
imputation was performed prior to the main analyses. In basic models we adjusted for age, sea-
son of blood collection and length of follow-up. In fully adjusted models we controlled for the
same covariates as the basic model as well as education, sex, BMI, smoking, alcohol consump-
tion and depressive symptoms.
In secondary analyses, we repeated the main analyses by classifying serum 25(OH)D con-
centrations as a binary variable using the following cut-points:<50 nmol/L and50 nmol/L.
We also analysed serum 25(OH)D concentrations as a continuous variable. Continuous serum
25(OH)D concentrations were standardised to have a mean of 0 and a SD of 1 and were then
normalised using a log transformation in order to address the positive skew.
In sensitivity analyses, the main analyses were rerun using propensity score weighting as
opposed to multiple imputation to account for the missing data. This was to investigate
whether either method of addressing missing data could bias the results. The variables used to
derive the propensity score weights were the same as those used in the multiple imputation
models. Additionally, the main analyses were repeated using only participants with complete
data in order to explore whether either multiple imputation or propensity score weighting
drastically alters the pattern of association. In the complete cases, 292 (28.7%) out of 1,017
developed worsening white matter grade, 275 (27.7%) out of 994 developed worsening ventric-
ular grade and 153 (17.8%) out of 851 developed incident infarcts.
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Multivariate logistic regression models were used to investigate the cross-sectional associa-
tion between clinically relevant categories of serum 25(OH)D concentrations and prevalent
white matter abnormalities (2 categories; grade<3 (N = 779) and grade3 (N = 239)) [27],
ventricular abnormalities (2 categories; grade<5 (N = 866) and grade5 (N = 129)) [27] and
infarcts (2 categories; present (N = 415) and absent (N = 1,237)).
P-values were two sided throughout with statistical significance preset at 0.05. Multiple
imputation, propensity score weighting and all statistical analyses were performed using Stata/
SE version 13 (StataCorp, College Station, Texas).
Results
Table 1 presents the baseline characteristics for the total population. Compared to those with
sufficient and deficient 25 (OH)D concentrations, participants with severe 25(OH)D deficiency
tended to be older, have blood collected between December and May, be less educated, female,
a smoker, have depressive symptoms, diabetes, treated hypertension and be of non-white eth-
nicity. There appeared to be little difference across categories of 25(OH)D concentrations in
alcohol use and untreated hypertension. There was no difference in follow-up length between
all categories of 25(OH)D concentrations.
Participants with complete MRI data for any neuroimaging outcome were followed up for a
mean of 5.0 years (N = 1,087), SD 0.6, median 5.0, range 3.2–7.5). In both minimally and fully
adjusted models, there was no significant association observed between clinically relevant cate-
gories of serum 25(OH)D and the risk of worsening white matter grade, worsening ventricular
grade or incident infarcts (Table 2). Similar findings were observed when entering serum 25
(OH)D in the models as a binary as opposed to a three group categorical variable (Table 3).
Furthermore, there was no significant association observed between log-transformed standard-
ised 25(OH)D concentrations and either worsening white matter grade (Odds Ratio [OR] =
1.04, 95% CI: 0.90–1.21, p = 0.59), worsening ventricular grade (OR = 1.05, 95% CI: 0.90–1.23,
p = 0.53) or incident infarcts (OR = 1.08, 95% CI: 0.89–1.30, p = 0.45) in multivariate adjusted
logistic regression models.
In sensitivity analyses, using propensity score weighting as opposed to multiple imputation
to account for missing data produced similar findings to the main analyses (Table 4). Addition-
ally, the observed associations between serum 25(OH)D concentrations and neuroimaging
abnormalities remained similar in participants with complete MRI data (Table 5).
In cross-sectional analyses, the odds of prevalent infarcts were 91% higher in those with
severe 25(OH)D deficiency compared to those with sufficient 25(OH)D concentrations in the
fully adjusted model (OR = 1.91, 95% CI 1.12–3.27) (Table 6). However there were no differ-
ences in the odds of prevalent infarcts in those with 25(OH)D deficiency compared to those
sufficient and the linear trend across all three categories was not significant (p = 0.15). Simi-
larly, there were no significant associations between the odds of prevalent white matter or ven-
tricular abnormalities and serum 25(OH)D concentrations.
Discussion
In this large US population-based prospective cohort study, after adjusting for a wide range of
potential confounders, we found no association between serum 25(OH)D concentrations and
the risk of developing incident neurodegenerative or cerebrovascular abnormalities in elderly
adults free from prevalent dementia, stroke and cardiovascular disease. The lack of association
was consistent when accounting for missing data through multiple imputation and propensity
score weighting, as well as restricting the analyses to complete cases. Severe 25(OH)D defi-
ciency was associated with an increased risk of prevalent infarcts compared to those with 25
Vitamin D and Risk of Neuroimaging Abnormalities
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(OH)D sufficiency; however there were no further associations between 25(OH)D concentra-
tions and prevalent neuroimaging abnormalities.
The only previous prospective study in the area did not observe any association between
vitamin D concentrations and the development of white matter hyperintensities and incident
infarcts [20]. However, the population consisted of younger adults with a mean age of 62.3
years as well as a high rate of missingness at the follow-up scan, both of which might have
restricted the possibility of observing significant associations [20]. We addressed these limita-
tions and also found no association with the development of white matter hyperintensities or
incident infarcts, additionally we did not observe an association with increased ventricular
atrophy.
Table 1. Baseline characteristics of 1,658 CHS Participants by serum 25(OH)D concentration.
Serum 25(OH)D, nmol/L
All 50 25 to <50 <25
Characteristic (n = 1,658) (n = 1,169) (n = 419) (n = 70)
Age (y), M(SD) 73.6 (4.5) 73.6 (4.4) 73.7 (4.6) 74.1 (5.1)
Season tested, No. (%)
Dec-Feb 363 (21.9) 207 (17.7) 133 (31.7) 23 (32.9)
Mar-May 383 (23.1) 207 (17.7) 144 (34.4) 32 (45.7)
Jun-Aug 475 (28.7) 407 (34.8) 60 (14.3) 8 (11.4)
Sep-Nov 437 (26.4) 348 (29.8) 82 (19.6) 7 (10.0)
Education (n = 1,655), No. (%)
Did not ﬁnish high school 366 (22.1) 243 (20.8) 103 (24.7) 20 (28.6)
Finished high school/some college /vocational 910 (55.0) 644 (55.1) 226 (54.2) 40 (57.1)
College/professional 379 (22.9) 281 (24.1) 88 (21.1) 10 (14.3)
Female, No. (%) 1148 (69.2) 756 (64.7) 330 (78.8) 62 (88.6)
BMI (kg/m2), M(SD) 26.5 (4.5) 26.1 (4.2) 27.7 (5.1) 27.4 (5.3)
Current smoker (n = 1,615), No. (%) 149 (9.2) 93 (8.2) 46 (11.2) 10 (14.7)
Alcohol use (n = 1,656), No. (%)a
Non-drinkers 898 (54.2) 613 (52.4) 245 (58.6) 40 (58.0)
Moderate drinkers 621 (37.5) 452 (38.7) 145 (34.7) 24 (34.8)
Heavy drinkers 137 (8.3) 104 (8.9) 28 (6.7) 5 (7.3)
Depressive symptoms (CES-D score 8), No. (%) 359 (21.7) 221 (18.9) 117 (27.9) 21 (30.0)
Diabetes, No. (%)b 175 (10.6) 95 (8.1) 64 (15.3) 16 (22.9)
Hypertension, No. (%)
Normal 696 (42.0) 526 (45.0) 151 (36.0) 19 (27.1)
Treated 639 (38.5) 412 (35.2) 189 (45.1) 38 (54.3)
Untreated 323 (19.5) 231 (19.8) 79 (18.9) 13 (18.6)
Years of follow-up (n = 1,087), M(SD) 5.0 (0.6) 5.0 (0.6) 5.0 (0.6) 5.0 (0.6)
White, No. (%) 1452 (87.6) 1088 (93.1) 322 (76.9) 42 (60.0)
White matter grade (n = 1,018), M(SD) 1.7 (1.4) 1.7 (1.4) 1.6 (1.3) 2.0 (1.4)
Ventricular grade (n = 995), M(SD) 3.1 (1.2) 3.2 (1.2) 2.9 (1.2) 3.3 (1.4)
Infarcts (n = 1,652), No. (%) 415 (25.1) 289 (24.8) 100 (23.9) 26 (37.7)
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index, CES-D, Center for Epidemiologic Studies Depression Scale[30] (revised 10 item
scale)
a National Institute on Alcohol Abuse and Alcoholism guidelines
b American Diabetic Association guidelines
doi:10.1371/journal.pone.0154896.t001
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These findings are in contrast with the majority of cross-sectional neuroimaging studies,
which have largely found consistent associations between lower vitamin D concentrations and
an increased risk of cerebrovascular and neurodegenerative abnormalities. Six cross-sectional
studies found that low vitamin D concentrations were significantly associated with more white
matter abnormalities [4,10,12,13,15,17], although three studies found no association with
white matter abnormalities or volume [6,8,19]. Whilst, one study found that vitamin D defi-
ciency (50 nmol/L) was associated with a 28% increase in lateral ventricle volume compared
to those with vitamin D sufficiency (>50 nmol/L) [8].
We found that severe 25(OH)D deficiency (<25 nmol/L) was associated with an increased
prevalence of infarcts compared to those with 25(OH)D sufficiency (50 nmol/L). This
Table 2. Odds ratio of developing neuroimaging abnormalities by 3 categories of serum 25(OH)D concentrations after multiple imputation.
Serum 25(OH)D, nmol/L
50 25 to <50 <25
Neuroimaging Outcome No. of participants OR OR (95% CI) OR (95% CI) p-value for linear trend
White matter grade
Model Aa 1,657 1 (Reference) 1.09 (0.78–1.53) 0.76 (0.36–1.64) 0.94
Model Bb 1,657 1 (Reference) 1.09 (0.76–1.55) 0.76 (0.35–1.66) 0.92
Ventricular grade
Model Aa 1,658 1 (Reference) 1.15 (0.83–1.60) 0.51 (0.21–1.22) 0.69
Model Bb 1,658 1 (Reference) 1.12 (0.79–1.59) 0.49 (0.20–1.19) 0.56
Infarcts
Model Aa 1,243 1 (Reference) 0.74 (0.49–1.13) 2.00 (0.86–4.61) 0.78
Model Bb 1,243 1 (Reference) 0.73 (0.47–1.13) 1.95 (0.84–4.54) 0.82
Abbreviations; OR, Odds Ratio; CI, Conﬁdence Interval
a Adjusted for age, season of vitamin D collection and length of follow-up
b Adjusted for Model A and education, sex, BMI, smoking, alcohol consumption and depressive symptoms
doi:10.1371/journal.pone.0154896.t002
Table 3. Odds ratio of developing neuroimaging abnormalities by 2 categories of serum 25(OH)D concentrations after multiple imputation.
Serum 25(OH)D, nmol/L
50 <50
Neuroimaging Outcome No. of participants OR OR (95% CI) p-value
White matter grade
Model Aa 1,657 1 (Reference) 1.03 (0.74–1.44) 0.84
Model Bb 1,657 1 (Reference) 1.03 (0.73–1.46) 0.85
Ventricular grade
Model Aa 1,658 1 (Reference) 1.05 (0.75–1.46) 0.79
Model Bb 1,658 1 (Reference) 1.01 (0.72–1.42) 0.95
Infarcts
Model Aa 1,243 1 (Reference) 0.86 (0.57–1.30) 0.46
Model Bb 1,243 1 (Reference) 0.86 (0.56–1.31) 0.48
Abbreviations; OR, Odds Ratio; CI, Conﬁdence Interval
a Adjusted for age, season of vitamin D collection and length of follow-up
b Adjusted for Model A and education, sex, BMI, smoking, alcohol consumption and depressive symptoms
doi:10.1371/journal.pone.0154896.t003
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association was also similar in the prospective analyses for incident infarcts, however it did not
reach statistical significance. There have been several studies that have implicated low vitamin
D concentrations in the development of infarcts. Adult rats treated with vitamin D3 via injec-
tion for a period of eight days demonstrated a significant reduction in middle cerebral arterial
litigation-induced cortical infarction in the cortex compared to control rats injected with saline
[32]. Furthermore, in a meta-analysis consisting of 26,596 participants, low 25(OH)D concen-
trations were prospectively associated with an increased risk of ischemic stroke [33]. In cross-
sectional neuroimaging studies, lower vitamin D concentrations are associated with increased
prevalence of large vessel infarcts [4], lacunar infarcts [15] as well as larger ischemic infarct
Table 4. Odds ratio of developing neuroimaging abnormalities by 3 categories of serum 25(OH)D concentrations after propensity score weighting.
Serum 25(OH)D, nmol/L
50 25 to <50 <25
Neuroimaging Outcome No. of participants OR OR (95% CI) OR (95% CI) p-value for linear trend
White matter grade
Model Aa 987 1 (Reference) 1.12 (0.77–1.63) 0.77 (0.34–1.75) 0.95
Model Bb 987 1 (Reference) 1.12 (0.77–1.64) 0.75 (0.34–1.69) 0.99
Ventricular grade
Model Aa 964 1 (Reference) 1.13 (0.78–1.63) 0.56 (0.23–1.38) 0.75
Model Bb 964 1 (Reference) 1.07 (0.74–1.55) 0.51 (0.21–1.26) 0.49
Infarcts
Model Aa 824 1 (Reference) 0.70 (0.43–1.13) 1.70 (0.70–4.11) 0.69
Model Bb 824 1 (Reference) 0.70 (0.42–1.15) 1.76 (0.72–4.29) 0.74
Abbreviations; OR, Odds Ratio; CI, Conﬁdence Interval
a Adjusted for age, season of vitamin D collection and length of follow-up
b Adjusted for Model A and education, sex, BMI, smoking, alcohol consumption and depressive symptoms
doi:10.1371/journal.pone.0154896.t004
Table 5. Odds ratio of developing neuroimaging abnormalities by 3 categories of serum 25(OH)D concentrations in participants with complete
MRI data.
Serum 25(OH)D, nmol/L
50 25 to <50 <25
Neuroimaging Outcome No. of participants OR OR (95% CI) OR (95% CI) p-value for linear trend
White matter grade
Model Aa 1,017 1 (Reference) 1.02 (0.72–1.45) 0.72 (0.33–1.55) 0.65
Model Bb 988 1 (Reference) 1.04 (0.72–1.49) 0.80 (0.36–1.76) 0.82
Ventricular grade
Model Aa 994 1 (Reference) 1.11 (0.79–1.58) 0.48 (0.19–1.17) 0.52
Model Bb 965 1 (Reference) 1.06 (0.74–1.52) 0.47 (0.19–1.16) 0.40
Infarcts
Model Aa 851 1 (Reference) 0.71 (0.44–1.12) 1.76 (0.77–4.03) 0.86
Model Bb 825 1 (Reference) 0.69 (0.43–1.12) 1.73 (0.71–4.19) 0.74
Abbreviations; OR, Odds Ratio; CI, Conﬁdence Interval
a Adjusted for age, season of vitamin D collection and length of follow-up
b Adjusted for Model A and education, sex, BMI, smoking, alcohol consumption and depressive symptoms
doi:10.1371/journal.pone.0154896.t005
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volume [18], but not small vessel infarcts [4]. It is possible that the small sample size in the cur-
rent study was too underpowered to detect a statistically significant association with incident
infarcts in those with severe 25(OH)D deficiency.
Our study has several strengths. It is the first large prospective study to investigate the asso-
ciation between 25(OH)D concentrations and the risk of developing neuroimaging abnormali-
ties in ambulatory elderly adults. We also utilised multiple imputation and propensity score
weighting to address attrition during follow-up. Scans one and two were assessed in a side-by-
side fashion for white matter and ventricular grade which improved rating reliability as
opposed to assessing the scans separately. In the current population, we previously identified a
strong association between low vitamin D concentrations and the risk of incident all-cause
dementia and AD [1] whilst the MRI scans were incorporated in the diagnosis of these condi-
tions [34]. Therefore, this population is well-suited to explore the potential cerebrovascular
and neurodegenerative mechanisms that underlie these observed associations using neuroim-
aging technology. Our study also has several limitations. 25(OH)D concentrations were only
measured in participants free from prevalent cardiovascular disease and stroke which might
have reduced the likelihood of them developing cerebrovascular abnormalities at follow-up.
This is supported by the low number of incident vascular dementia cases (N = 15) found in the
population. However, of the complete cases, 28.7% developed worsening white matter grade
and 18% developed incident infarcts, which should be sufficient to detect an association. The
outcomes were assessed by two neuroradiologists, which is likely to have introduced a degree
of subjective bias and human error, whereas quantitative software tools would have provided
higher degree of precision. Similarly it would have been useful to have quantitative measures of
white matter and ventricular volume as opposed to relying on a 10-point scale score. Length of
follow-up ranged from 3.2 to 7.5 years, so it is possible that those who were scanned within the
lower range did not have an adequate amount of time to develop neuroimaging abnormalities.
Despite using methods to address the issue of missing data at follow-up it is possible that this
was not sufficient to account for the possibility of non-random attrition. It is also possible that
measurement error could have been introduced when assessing the neuroimaging outcomes at
two different time points, although this is unlikely to have resulted in systematic bias.
Table 6. Odds ratio of prevalent neuroimaging abnormalities by 3 categories of serum 25(OH)D concentrations in participants with complete MRI
data at baseline.
Serum 25(OH)D, nmol/L
50 25 to <50 <25
Neuroimaging Outcome No. of participants OR OR (95% CI) OR (95% CI) p-value for linear trend
White matter grade
Model Aa 1,018 1 (Reference) 0.75 (0.51–1.10) 1.41 (0.70–2.85) 0.75
Model Bb 989 1 (Reference) 0.76 (0.51–1.13) 1.29 (0.62–2.70) 0.65
Ventricular grade
Model Aa 995 1 (Reference) 0.63 (0.38–1.04) 1.34 (0.58–3.10) 0.48
Model Bb 966 1 (Reference) 0.71 (0.41–1.20) 1.49 (0.60–3.66) 0.78
Infarcts
Model Aa 1,652 1 (Reference) 1.02 (0.78–1.34) 1.98 (1.18–3.34) 0.08
Model Bb 1,609 1 (Reference) 0.98 (0.74–1.30) 1.91 (1.12–3.27) 0.15
Abbreviations; OR, Odds Ratio; CI, Conﬁdence Interval
a Adjusted for age, season of vitamin D collection and length of follow-up
b Adjusted for Model A and education, sex, BMI, smoking, alcohol consumption and depressive symptoms
doi:10.1371/journal.pone.0154896.t006
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In elderly US-based adults free from prevalent dementia, stroke and cardiovascular disease
we found that vitamin D concentrations at baseline were not prospectively associated with the
risk of developing worsening white matter grade, worsening ventricular grade or incident
infarcts. However, there was a non-significant tendency towards an increased risk of incident
infarcts in those with severe 25(OH)D deficiency compared to those sufficient. Given the limi-
tations, such as a high proportion of participants lost to follow-up, further prospective neuro-
imaging studies incorporating a wider range of cerebrovascular and neurodegenerative
abnormalities measured with greater precision are warranted.
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